1. Australia Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Nexsen Limited

Nexsen Limited

AASX:NXN
0.16
AUD
+0.01
(+6.67%)
-0.04EPS
50.05MMarket Cap
Nexsen Limited
ASX:NXN
(Australian Securities Exchange)

Recent

price

0.16

P/E

ratio

- -

div

yld

- -

ROIC.AI

2025
2026
AUD
- -
- -
Revenue per Share
- -
-0.04
Basic EPS, GAAP
- -
- -
Free Cash Flow per Basic Share
- -
- -
Dividend per Share
- -
0.03
Book Value per Share
- -
0.02
Tangible Book Value per Share
200
180
Basic Weighted Avg Shares
- -
- -
Sales/Revenue/Turnover
- -
- -
Operating Margin (%)
- -
- -
Depreciation Expense
- -
-7
Net Income, GAAP
- -
- -
Effective Tax Rate (%)
- -
- -
Profit Margin (%)
- -
4
Working Capital
- -
- -
LT Debt
- -
6
Total Equity
- -
- -
Return on Invested Capital (%)
- -
- -
Return on Capital (%)
- -
- -
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2025
- -
- -
- -
2026
- -
- -
-0.04

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Nexsen Ltd. operates as a nano-biotechnology company, which develops lab-quality diagnostics and sensors. Its product pipeline includes a GBS rapid sensor, chronic kidney disease, bovine mastitis, acute kidney injury and biosecurity pathogen tests. The company was founded by Mark Anthony Muzzin in 2021 and is headquartered in Sydney, Australia.